NAVLIN Daily NewsCheckout Today’s News
Poland’s Council of Ministers has adopted the draft amendment to the country’s medicines reimbursement law, with the majority of amendments coming into force from January 1, 2027As reported earlier this month, Mateusz Oczkowski, director of the Ministry of Health’s Department of Drug Policy and Pharmacy, told the Polish Press Agency (PAP) that the draft was released from the Legal Committee on October 13, adding that he expected it to reach government on October 20One of the proposed changes would introduce a price-reduction mechanism following the expiry of market exclusivity. Under the draft, the net selling price in the first reimbursement decision issued after the relevant exclusivity period would generally be limited to 75% of the price established in the first reimbursement decision. The proposal also provides for changes to risk-sharing arrangements and mechanisms intended to control public expenditure on reimbursed medicines
Last week, NAVLIN Daily brought you key market access developments from across the globe France’s lawmakers rejected the social security financing bill amid debate over pharma contributions and medicine reassessment, while China proposed blacklisting biotech platform exports and restricting technology transfers on national security grounds In its October meeting, the EMA Committee for Medicinal Products for Human Use (CHMP) recommended six new medicines for approval, including five indication extensions. The recommendations include Yuviwel (navepegritide), Kizfizo (temozolomide), and Foundayo (orforglipron)
The U.S. Treasury plans to restrict American pharmaceutical investments in China, targeting financing, joint ventures, and acquisitionsBeijing said the move was excessive and warned of potential countermeasures to protect its interests, urging the U.S. to maintain stable global supply chainsThe proposed U.S. rules don't cover common licensing or R&D deals, but would tighten scrutiny on NewCo models and other financing and equity-based arrangements
The UK Parliament’s Health and Social Care Committee has urged the government to accelerate National Health Service (NHS) access to weight-loss medicines and overhaul obesity services in England, warning that fragmented care and restricted access to treatment are deepening health inequalities“Weight-loss drugs have been a positive innovation, but they remain out of reach for those who can’t afford them,” stated Health and Social Care Committee Chair Layla Moran MP. “A two-tier system has emerged because of limited supply via the NHS, inadvertently deepening health inequalities. This needs to be reviewed and streamlined with input from digital providers”Overall, in its report on ‘Food and Weight Management: Modernizing obesity treatment,’ the cross-party Committee calls for obesity to be recognized consistently as a lifelong, chronic and relapsing condition, requiring ongoing management similar to type 2 diabetes
Poland’s Ministry of Health has proposed amending eight laws to improve access to medicines for patients who have exhausted available treatment options, including introducing up to 12 months of transitional funding for effective therapies after pre-registration access programs endThe proposal would replace the Emergency Access to Drug Technologies (RDTL) pathway with a new mechanism called Transitional Financing of Drug Technologies (PFTL), with standardized applications, expert medical assessments, and deemed approval if the National Health Fund (NFZ) does not respond within seven daysOther measures include allowing patients to apply for and track reimbursement of imported medicines through the Internet Patient Account and extending Medical Fund financing for one-time advanced therapies to adults with rare diseases
China has drafted market exclusivity rules for rare disease and pediatric drugs. Rare disease treatments could receive four to seven years of exclusivity, while pediatric drugs may see one to two years, based on the product category and launch timingCompanies must apply for exclusivity during product registration, and applicants are required to ensure steady supply levelsPediatric and rare disease exclusivity can’t be combined. If a product’s exclusivity period overlaps with clinical data protection, it will begin after data protection ends
Abbott’s Nutrition business is breaking off to become its own publicly traded company by the end of 2027The new Nutrition company expects to pull in around $8.5 billion in annual salesIt will focus on metabolic health, wellness, and prevention, serving both developed and emerging markets
Maruho struck a deal with Incyte to bring ruxolitinib cream to South Korea for atopic dermatitisThe Japan-based company will handle development, manufacturing, and commercialization activitiesRuxolitinib cream, a dual JAK1/JAK2 inhibitor, is already approved for vitiligo and atopic dermatitis in the U.S. and Europe
Roche and Hansoh Pharmaceutical inked a massive $15 billion deal, focusing on cutting-edge antibody-drug conjugates (ADCs), marking the second ADC-centered arrangement between the two playersThe pact covers two preclinical assets from Hansoh, as well as multiple programs stemming from Hansoh’s tech platformOn the same day, Roche hit pause on future investments in Germany, citing broken trust from recent cost-cutting measures
The UK’s National Audit Office (NAO) will begin inquiries into the costs and value for money of the UK-U.S. pharmaceutical pricing agreement, following a request from six parliamentary committee chairs. The watchdog’s move comes amid continued concerns over the government’s refusal to publish the full impact assessment for the deal, citing commercial sensitivityEarlier this year, the Nuffield Trust filed a request for an impact assessment with the Department of Health and Social Care (DHSC). However, its request was denied, as was a follow-up request to review that decisionMeanwhile, in a letter dated September 30, 2026, to Layla Moran MP, Chair of the House of Commons Health and Social Care Committee, the NAO Comptroller and Auditor General, Gareth Davies, confirmed that he had instructed his team to make preliminary inquiries into the agreement. He said he would write again to the committee chairs once the initial inquiries were complete
650+
+99%
<24
4,000+
24x7
99.5%
